Seven weeks in, great people, great passion and great work done. - Recensione dipendente - Head of Talent Acquisition presso Novacyt Group

5,0
29 giu 2022
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

This is early days for me in the company and after an extremely busy two years for Novacyt helping to combat the Covid Pandemic. It is great to be back in the BioTech world. The company has products that help detect infectious diseases - Covid and Monkey Pox included. The company grew at a tremendous rate from 2019 until recently, in terms of numbers of employees and revenues. The growth was at such a rate that some of the process, perfectly good when so much smaller, are now being reviewed and processes suitable for today and the future being rolled out. I am delighted to have helped expedite four people being moved from one team to another and others being promoted. There is a comprehensive benefits package: Pension Life Assurance Bonus Scheme 25 days holiday (+ public holidays)

Svantaggi

None that I can see, which are not being sorted. There is a will to move things forward and a real energy to get things done.

Esplora altre recensioni su Novacyt Group

1,0
8 set 2022
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

The small number of core people who cared and wanted to help and support end-users in challenging times.

Svantaggi

Higher management (now departed CCO for example) had little post-Covid actions/plans. Proposals of alternative areas to grow into (from sales teams on numerous occasions) were not recognised until it was very evident that covid testing demands were on the downturn. It’s unfortunate that there was lack of future planning based on utilising instrument install base to leverage the promate solution/technology within public and private sectors. The portfolio of RUO assays was strong but needed updated. If they were maintained it would have given a strong start to post covid markets prior to gaining CE-IVD/IVDR There was a toxic working environment within and between some commercial divisions. The lack of a proper e-commerce platform is telling of the position of where Novacyt currently is.

4
avatar
Risposta di Novacyt Group
3y
When the Covid Pandemic struck, Novacyt was uniquely positioned to provide the tests to detect the virus in a very speedy manner, and to develop these as the various strains evolved. The company grew in terms of revenue, customer numbers and of course staff numbers to support the battle against Covid. The business did recognise that Covid testing demands would reduce and work was done to build up other business areas. Novacyt is interested primarily in technologies applied to human infectious disease diagnostics and screening, and adjacent markets. These include: Respiratory, Gastrointestinal, Transplant, Insect-borne diseases. We are also considering additional unmet needs in infectious diseases including sexually transmitted infections (STI), urinary tract infections (UTI), hospital acquired infections, meningitis/encephalitis and sepsis. There are some business areas which we have now withdrawn from, as they did not sit in our focus, which is very much on infectious diseases. With very deep regret a number of posts were made redundant and after a period of consultation, sadly a number of people left the organisation. However, they left knowing the impact they made to the battle against Covid, the big impact that they and the company had on fighting the pandemic, and left with skills and experience gained during this unique period of world history.
2,0
13 apr 2025
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Friendly lab staff in all departments

Svantaggi

Unfriendly and poor management in all departments

Vedi recensioni per: Utile|Valutazione|Data|Tutto